Menu
x
Investors & Newsroom
Culture & Careers
Who we are
Who we are
Overview
Pioneers In Gene Therapy
Mission & Values
Management Team
Board of Directors
Science & innovation
Science & innovation
Overview
What is AAV Gene Therapy?
NAV® Technology Platform
Partners & Licensees
Manufacturing
Publications
Therapeutic pipeline
Therapeutic pipeline
Overview
ABBV-RGX-314 for Retinal Diseases
RGX-202 for Duchenne
RGX-121 for MPS II (Hunter Syndrome)
Patients & families
Patients & families
Overview
Why Gene Therapy?
Wet AMD
Duchenne
MPS II
Expanded Access
Search
Investors & Newsroom
Culture & Careers
Media
Presentation & Publications
RGX-121 Gene Therapy for the Treatment of Severe Mucopolysaccharidosis Type II (MPS II): CAMPSIITE® Phase I/II/III: A Clinical Study Update
Roberto Giugliani, M.D., Ph.D., Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil